# Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC

Source: https://onco.cc/trials/nct07698106/  
OnCo record `nct07698106` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by University Health Network, Toronto, not yet recruiting.

## Summary

Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC is a phase 1/2, randomised interventional study registered as NCT07698106 by University Health Network, Toronto, with a registry enrolment figure of 60 participants, started 2026-08 and due to reach its primary completion in 2034-08. Interventions recorded: Group 1-Isunakinra. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Newly diagnosed, locally advanced, previously untreated and centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines, and staging per current AJCC staging criteria for breast cancer as assessed by the inves". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07698106
- Phase: 1/2
- Setting: Rebooting Sensitivity to Checkpoint Blockade Therapy in Triple-Negative Breast Cancer With Isunakinra (RESETT- I)
- Sponsor: University Health Network, Toronto
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07698106: https://clinicaltrials.gov/study/NCT07698106

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07698106.json